NRX Pharmaceuticals Inc NRXP.OQ NRXP.O is expected to show a rise in quarterly revenue when it reports results on May 15 for the period ending March 31 2025
The Wilmington Delaware-based company is expected to report revenue of $1.138 million, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for NRX Pharmaceuticals Inc is for a loss of 30 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for NRX Pharmaceuticals Inc is $25.00, above its last closing price of $2.08.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.31 | -0.32 | -0.77 | Missed | -143.2 |
Sep. 30 2024 | -0.59 | -0.64 | -0.13 | Beat | 79.7 |
Jun. 30 2024 | -0.68 | -0.69 | -0.67 | Beat | 3.6 |
Mar. 31 2024 | -0.55 | -0.55 | -0.74 | Missed | -34.5 |
Dec. 31 2023 | -0.63 | -0.70 | -0.50 | Beat | 28.6 |
Sep. 30 2023 | -1.15 | -1.13 | -0.70 | Beat | 38.2 |
Jun. 30 2023 | -1.50 | -1.37 | -1.20 | Beat | 12.2 |
Mar. 31 2023 | -1.40 | -1.40 | -1.60 | Missed | -14.3 |
This summary was machine generated May 13 at 20:26 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。